Scotiabank raised the firm’s price target on Bristol Myers (BMY) to $53 from $45 and keeps a Sector Perform rating on the shares. The firm expects many pivotal and registrational data readouts in 2026, believing the risk/reward for these upcoming readouts is to the upside, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Sell Rating on Bristol-Myers Squibb Due to Cobenfy Trial Challenges and Uncertain Sales Forecast
- Leerink views ADEPT-2 update as positive news, keeps Outperform on Bristol Myers
- ADEPT-2 news ‘at face is a win’ for MapLight Therapeutics, says Stifel
- Eli Lilly Stock (LLY) Gets Multiple Price Target Increases as Rally Continues
- Bristol Myers ADEPT-2 update an ‘incremental positive,’ says JPMorgan